Table 3.
Associations between cervical HPV DNA, HIV-1 serostatus and cytology and incident genital warts among a sub-group of 306 women
| Characteristic | Number of events/person-years | Unadjusted HRa (95% CI) | Adjusted HRb (95% CI) | P-value |
|---|---|---|---|---|
| Cervical HPV DNA at baseline | ||||
| HPV-6 positive, yes vs. no | ||||
| Effect in 1st year of follow-up | 4/17 | 8.67 (1.86-40.40) | 9.09 (1.75-47.29) | 0.009 |
| Effect after 1st year of follow-up | 1/12 | 0.12 (0.03-0.54) | 0.11 (0.02-0.57) | 0.009 |
| HPV-11 positive, yes vs. no | 1/21 | 0.74 (0.07-7.58) | 1.17 (0.11-12.37) | 0.89 |
| HPV-52 positive, yes vs. no | 9/50 | 3.73 (1.28-10.83) | 3.81 (0.90-16.23) | 0.07 |
| Other HPV types, negative for types 6, 11,52 | 19/226 | 1.48 (0.64-3.45) | 2.64 (0.62-11.33) | 0.19 |
| Cervical cytology at baseline (N = 296) | ||||
| Normal | 9/369 | 1.0 | 1.0 | |
| ASCUS/LSIL/HSIL | 23/134 | 7.38 (3.10-17.56) | 3.05 (1.17-7.92) | 0.02 |
| HIV status, nadir CD4+ count | ||||
| HIV seronegative | 4/289 | 1.0 | ||
| HIV-1+, CD4 >200cells/μL | 11/119 | 3.22 (0.71-14.59) | 0.13 | |
| HIV-1+, CD4 ≤200 cells/μL | 18/79 | 10.94 (2.60-46.12) | 0.001 |
Note. HR: hazard ratio; CI, confidence interval; ASCUS, atypical squamous changes of unknown significance; LSIL/HSIL, low/high squamous intraepithelial lesions.
a Determined by Cox regression with shared frailty; b Model also included age group, history of pregnancy, history of smoking, hormonal contraception, education less than or greater than primary and number of sexual partners in past week. For those factors not conforming to proportional hazards, a parameter was added to determine the impact in the first year of follow-up compared to after one year.